Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations

Kevin Hauser, Christopher Negron, Steven K. Albanese, Soumya Ray, Thomas Steinbrecher, Robert Abel, John D. Chodera, and Lingle Wang.
Communications Biology 1:70, 2018 [DOI] [input files and analysis scripts]

In our first collaborative paper with Schrödinger, we present the first comprehensive benchmark assessing the ability for alchemical free energy calculations to predict clinical mutational resistance or susceptibility to targeted kinase inhibitors using the well-studied kinase Abl, the target of therapy for chronic myelogenous leukemia (CML).

Quantitative self-assembly prediction yields targeted nanomedicines

Yosi ShamayJanki Shah, Mehtap Işık, Aviram MizrachiJosef LeiboldDarjus F. TschaharganehDaniel RoxburyJanuka Budhathoki-UpretyKarla NawalyJames L. SugarmanEmily BautMichelle R. NeimanMegan DacekKripa S. GaneshDarren C. JohnsonRamya SridharanKaren L. ChuVinagolu K. RajasekharScott W. Lowe, John D. Chodera, and Daniel A. Heller. 
Nature Materials 17:361, 2018. [DOI] [PDF] [Supporting Info] [nano-drugbank]

In a collaboration with the Heller Lab at MSKCC, we show how indocyanine nanoparticles can package insoluble selective kinase inhibitors with high mass loadings and efficiently deliver them to tumors.